AFT Pharmaceuticals Limited
AFT Pharmaceuticals Limited (AFP.AX) Financial Performance & Income Statement Overview
Review AFT Pharmaceuticals Limited (AFP.AX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
AFT Pharmaceuticals Limited (AFP.AX) Income Statement & Financial Overview
View the income breakdown for AFT Pharmaceuticals Limited AFP.AX across both annual and quarterly reports.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $86.71M | $111.80M | $83.61M | $90.89M |
| Cost of Revenue | $50.51M | $59.46M | $47.68M | $46.59M |
| Gross Profit | $36.20M | $52.34M | $35.94M | $44.30M |
| Gross Profit Ratio | $0.42 | $0.47 | $0.43 | $0.49 |
| R&D Expenses | $5.30M | $5.33M | $3.51M | $3.66M |
| SG&A Expenses | $32.70M | $28.83M | $29.27M | $26.96M |
| Operating Expenses | $38.002M | $31.35M | $32.77M | $29.16M |
| Total Costs & Expenses | $88.52M | $90.81M | $80.45M | $75.75M |
| Interest Income | $0.00 | $72000.00 | $532000.00 | $1.47M |
| Interest Expense | $0.00 | $3.74M | $1.81M | $0.00 |
| Depreciation & Amortization | $726000.00 | $1.53M | $848000.00 | -$465000.00 |
| EBITDA | -$1.08M | $22.51M | $4.63M | $15.75M |
| EBITDA Ratio | -$0.01 | $0.20 | $0.06 | $0.17 |
| Operating Income | -$1.80M | $20.98M | $3.17M | $16.21M |
| Operating Income Ratio | -$0.02 | $0.19 | $0.04 | $0.18 |
| Other Income/Expenses (Net) | -$1.04M | -$934000.00 | -$1.20M | -$2.54M |
| Income Before Tax | -$2.84M | $20.05M | $1.97M | $13.68M |
| Income Before Tax Ratio | -$0.03 | $0.18 | $0.02 | $0.15 |
| Income Tax Expense | -$383000.00 | $6.26M | $152000.00 | $4.57M |
| Net Income | -$2.19M | $13.79M | $1.82M | $9.11M |
| Net Income Ratio | -$0.03 | $0.12 | $0.02 | $0.10 |
| EPS | -$0.02 | $0.12 | $0.02 | $0.09 |
| Diluted EPS | -$0.02 | $0.12 | $0.02 | $0.09 |
| Weighted Avg Shares Outstanding | $109.30M | $118.93M | $104.87M | $104.87M |
| Weighted Avg Shares Outstanding (Diluted) | $109.30M | $118.93M | $104.87M | $104.87M |
Financial performance has remained strong, with revenue growing from $90.89M in Q4 2023 to $86.71M in Q2 2025. Gross profit continued to perform well, with margins at 42% in the latest quarter. Operating income reached -$1.80M in Q2 2025, holding a steady -2% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.08M. Net income dropped to -$2.19M, keeping EPS at -$0.02. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan